Mineralys Therapeutics, Inc. MLYS
We take great care to ensure that the data presented and summarized in this overview for Mineralys Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MLYS
Top Purchases
Top Sells
About MLYS
Insider Transactions at MLYS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,940
-1.59%
|
$164,340
$11.73 P/Share
|
|
Jun 18
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,607
-1.73%
|
$182,677
$11.99 P/Share
|
|
Jun 17
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
17,766
-1.82%
|
$213,192
$12.25 P/Share
|
|
Jun 14
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,229
-1.64%
|
$194,748
$12.52 P/Share
|
|
Jun 13
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
39,961
-3.87%
|
$479,532
$12.74 P/Share
|
|
Jun 12
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,607
-1.58%
|
$199,284
$12.77 P/Share
|
|
Jun 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+6.61%
|
$6,349
$1.08 P/Share
|
|
Jun 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+5.68%
|
$0
$0.54 P/Share
|
|
Jun 11
2024
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
96,815
-27.48%
|
$1,161,780
$12.94 P/Share
|
|
May 13
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,366
+7.0%
|
$0
$0.81 P/Share
|
|
May 09
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100
-0.15%
|
$1,500
$15.0 P/Share
|
|
May 09
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.15%
|
$100
$1.08 P/Share
|
|
Apr 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+8.66%
|
$6,349
$1.08 P/Share
|
|
Apr 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+7.64%
|
$0
$0.54 P/Share
|
|
Mar 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+10.24%
|
$6,348
$1.08 P/Share
|
|
Mar 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+9.24%
|
$0
$0.54 P/Share
|
|
Feb 12
2024
|
Samsara Bio Capital Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
555,555
+9.87%
|
$7,222,215
$13.5 P/Share
|
|
Feb 12
2024
|
Srinivas Akkaraju Director |
BUY
Grant, award, or other acquisition
|
Indirect |
555,555
+9.87%
|
$7,222,215
$13.5 P/Share
|
|
Feb 12
2024
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
1,672,508
+35.92%
|
$21,742,604
$13.5 P/Share
|
|
Feb 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,366
+12.11%
|
$0
$0.81 P/Share
|
Last 12 Months Summary
Buy / Acquisition
3.11M
Shares
From
5
Insiders
| Grant, award, or other acquisition | 2.23M shares |
|---|---|
| Open market or private purchase | 566K shares |
| Exercise of conversion of derivative security | 320K shares |
Sell / Disposition
451K
Shares
From
3
Insiders
| Open market or private sale | 451K shares |
|---|